Replies to post #204894 on Biotech Values

[DewDiligence]

ARLZ -30% on soft 4Q16 results/2017 guidance:

http://finance.yahoo.com/news/aralez-reports-fourth-quarter-full-103000069.html

ARLZ’s business plan appears involves acquiring unwanted assets from Big Pharma (e.g. #msg-125563785, #msg-125008718).

The company is the result of a reverse merger announced in 2015 (#msg-114404029) and consummated in 2016 (#msg-120344781).